Stage III NSCLC Treatment Patterns in Spain: A Population-Based Study of the GOECP-SEOR

<b>Objective:</b> We aimed to provide real-world insights into the management of non-small cell lung cancer stage III (NSCLC-SIII) in Spain. <b>Methods:</b> The GOECP-SEOR group conducted an observational, retrospective, multicenter study in which data from patients diagnosed with NSCLC-SIII treated in Spanish radiotherapy departments (RTDs) were collected. <b>Results:</b> A total of 1505 NSCLC-SIII patients from 35 RTDs from 2018 to 2021 were recruited. A total of 871 patients (57.9%) received concurrent chemoradiotherapy (cCRT), and 390 patients (25.91%) received maintenance durvalumab. The immunotherapy (IT) was well tolerated, with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0-2 toxicity observed in 85% of the patients (295 patients). The median overall survival (OS) was 26 months (95% CI 9.4-Not Reached NR). There was a statistically significant difference when patients were stratified by IT, with a median OS of 40 months (95% CI 22.1-NR) in the IT maintenance cohort compared with 19.4 months (95% CI 7.1-58.1) in the non-IT cohort. Differences were also noted in progression-free survival (PFS), with a median PFS of 20.8 months (95% CI 9.6-NR) in the IT cohort versus 8.4 months (95% CI 3.1-25.1) in the non-IT cohort. These differences remained significant according to the multivariate model (OS: HR 0.45 [95% CI 0.36-0.56], <i>p</i> < 0.001; PFS: HR 0.5 [95% CI 0.42-0.59], <i>p</i> < 0.001). <b>Conclusions:</b> The management of NSCLC-SIII patients can vary, leading to differences in treatment outcomes. The treatment of lung cancer in NSCLC-SIII patients in RTDs across Spain aligns with international guidelines and expert recommendations.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2025-11-27
DOI
https://doi.org/10.3390/cancers17233807
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Stage III NSCLC Treatment Patterns in Spain: A Population-Based Study of the GOECP-SEOR

Pino Alcántara, Paloma Sosa‐Fajardo, Laura Guzmán-Gómez, Víctor Duque‐Santana et al.
Cancers
Lung Cancer Diagnosis and Treatment
article

Stage III NSCLC Treatment Patterns in Spain: A Population-Based Study of the GOECP-SEOR

Pino Alcántara, Paloma Sosa‐Fajardo, Laura Guzmán-Gómez, Víctor Duque‐Santana, Patricia Valencia Nieto, María Mateos-Domínguez, A. Kannemann, Clara Eíto-Valdovinos, M. De los Santos-Rodríguez, M. Murcia, José Luis López Guerra, Felipe Couñago, Piedad Almendros-Blanco, Alicia Olarte-García, Patricia Barrionuevo-Castillo, M. López-Mata, María Ángeles González Ruiz, Sofía Sánchez-García, C. Cigarral, M. Rico, Javier Serrano, Carmen Vallejo-Ocaña, Amadeo Wals-Zurita, Sara Garduño-Sánchez, N.A. Linares-Mesa, Elías Gomis Sellés, M. Martín, Luis Leonardo Guerrero, Marina Peña, G. Potdevin-Stein, Manuel Luis Blanco-Villar, José Zapatero-Ortuño, Andrea Bobo-Jaureguizar, Javier Luna-Tirado, Nuria Farré-Bernadó, Victoria Vera-Barragán, Beatriz Vázquez-Barreiro, Germán Valtueña-Peydró, José A. González, Ana-María Álvarez-González, José-Enrique Castro-Gómez, Paula Martín-Barrientos, Paula Simón-Silva, Mariana-Teresa Peña-Perea, Miguel Montijano-Linde, Sara Pedraza-Fernández, Maximiliano Martos-Alcalde, Raúl Hernanz-Lucas, Celia García-Torres, Guillermo Cameselle-Gallego, Sonia Flamarique-Andueza, Francesc Casas-Duran, Elisabet González-Portillo, Patricia Diezhandino-García, Marcos Guijarro-Verdu, Paloma Moreno-Ceano, Aurea Manso-Lema, María Pagola-Divassón, Beatriz Moreno-Fuentes, Amalia Sotoca-Ruiz, Abrahams Ocanto-Martínez, Ana-Belén Bezares-Alarcón, Marta Rodríguez-Roldán
article en

Abstract

<b>Objective:</b> We aimed to provide real-world insights into the management of non-small cell lung cancer stage III (NSCLC-SIII) in Spain. <b>Methods:</b> The GOECP-SEOR group conducted an observational, retrospective, multicenter study in which data from patients diagnosed with NSCLC-SIII treated in Spanish radiotherapy departments (RTDs) were collected. <b>Results:</b> A total of 1505 NSCLC-SIII patients from 35 RTDs from 2018 to 2021 were recruited. A total of 871 patients (57.9%) received concurrent chemoradiotherapy (cCRT), and 390 patients (25.91%) received maintenance durvalumab. The immunotherapy (IT) was well tolerated, with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0-2 toxicity observed in 85% of the patients (295 patients). The median overall survival (OS) was 26 months (95% CI 9.4-Not Reached NR). There was a statistically significant difference when patients were stratified by IT, with a median OS of 40 months (95% CI 22.1-NR) in the IT maintenance cohort compared with 19.4 months (95% CI 7.1-58.1) in the non-IT cohort. Differences were also noted in progression-free survival (PFS), with a median PFS of 20.8 months (95% CI 9.6-NR) in the IT cohort versus 8.4 months (95% CI 3.1-25.1) in the non-IT cohort. These differences remained significant according to the multivariate model (OS: HR 0.45 [95% CI 0.36-0.56], <i>p</i> < 0.001; PFS: HR 0.5 [95% CI 0.42-0.59], <i>p</i> < 0.001). <b>Conclusions:</b> The management of NSCLC-SIII patients can vary, leading to differences in treatment outcomes. The treatment of lung cancer in NSCLC-SIII patients in RTDs across Spain aligns with international guidelines and expert recommendations.

CancersVol. 17(23)
Endesa (Spain) (ES), Universidad de Salamanca (ES), Hospital Universitario La Paz (ES), Hospital de Sant Pau (ES), University Hospital Complex Of Vigo (ES), Hospital General Universitario Gregorio Marañón (ES), Hospital Clínico San Carlos (ES), Research Institute Hospital 12 de Octubre (ES), Hospital Universitario de Torrejón (ES), Hospital Universitario Virgen Macarena (ES), Hospital La Luz (ES), Clinic IMQ Zorrotzaurre (ES), Hospital Universitario de Gran Canaria Doctor Negrín (ES), Fundación Valle del Lili (CO), Complejo Hospitalario de Salamanca (ES), Hospital Universitario Rey Juan Carlos (ES), Hospital Universitario 12 De Octubre (ES), Hospital Universitario Quirónsalud Madrid (ES), Hospital Quirónsalud Barcelona (ES), Hospital Clínic de Barcelona (ES), Complejo Hospitalario de Jaén (ES), Madrid Health Service (ES), Gibraltar Health Authority (GI), Hospital General Universitario De Valencia (ES), Hospital Juan Ramón Jiménez (ES), Hospital Universitario Fundación Jiménez Díaz (ES), Clinica Universidad de Navarra (ES), Hospital Clínico Universitario Lozano Blesa (ES), Centro de Implantología Cirugía Oral y Maxilofacial (ES), Onkologikoa (ES), Hospital Universitari Sant Joan de Reus (ES), Hospital Ruber Internacional (ES), Complejo Hospitalario Torrecárdenas (ES), Hospital Universitario Virgen del Rocío (ES), Hospital Clínico Universitario de Valladolid (ES), Hospital Universitario Ramón y Cajal (ES), Complejo Hospitalario de Ourense (ES), Universidad de Málaga (ES), Universidad de Navarra (ES), Universidad Europea de Madrid (ES)
Openalex Percentile: Top 45%
Lung Cancer Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.